{
    "organizations": [],
    "uuid": "b8ca20f3815df7ef4e04bf6d6ab68a38ae666980",
    "author": "",
    "url": "https://www.reuters.com/article/brief-kamada-announces-collaboration-wit/brief-kamada-announces-collaboration-with-hospitals-to-evaluate-its-product-for-preemption-of-type-of-graft-versus-host-disease-idUSFWN1OZ0MF",
    "ord_in_thread": 0,
    "title": "BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 12:12 PM / Updated 10 minutes ago BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease Reuters Staff 1 Min Read \nJan 4 (Reuters) - Kamada Ltd: \n* KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE \n* KAMADA SAYS ANNOUNCED COLLABORATION WITH MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM \n* KAMADA LTD - RECEIVED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE ALPHA-1 ANTITRYPSIN FOR PREEMPTION OF GVHD USING MAGIC BIOMARKERS \n* KAMADA SAYS STUDY OF ALPHA-1-ANTITRYPSIN WILL BE INITIATED IN Q1 OF 2018 \n* KAMADA LTD - TOP-LINE RESULTS FROM ALPHA-1-ANTITRYPSIN STUDY ARE EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T14:12:00.000+02:00",
    "crawled": "2018-01-04T14:36:27.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "collaboration",
        "hospital",
        "evaluate",
        "product",
        "preemption",
        "type",
        "disease",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "kamada",
        "ltd",
        "kamada",
        "announces",
        "collaboration",
        "consortium",
        "prominent",
        "hospital",
        "led",
        "mount",
        "sinai",
        "hospital",
        "evaluate",
        "antitrypsin",
        "product",
        "preemption",
        "steroid",
        "refractory",
        "acute",
        "disease",
        "kamada",
        "say",
        "announced",
        "collaboration",
        "mount",
        "sinai",
        "acute",
        "gvhd",
        "international",
        "consortium",
        "kamada",
        "ltd",
        "received",
        "exclusive",
        "right",
        "develop",
        "commercialize",
        "antitrypsin",
        "preemption",
        "gvhd",
        "using",
        "magic",
        "biomarkers",
        "kamada",
        "say",
        "study",
        "initiated",
        "q1",
        "kamada",
        "ltd",
        "result",
        "study",
        "expected",
        "available",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}